Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study by Athyros, Vassilios G. et al.
Safety and impact on cardiovascular events of long-term
multifactorial treatment in patients with metabolic
syndrome and abnormal liver function tests: a post hoc
analysis of the randomised ATTEMPT study 
Vassilios G. Athyros
1, Olga Giouleme
2, Emmanouel S. Ganotakis
3, Moses Elisaf
4, 
Konstantinos Tziomalos
3, Themistoklis Vassiliadis
3, Evangelos N. Liberopoulos
5, Eleni Theocharidou
6,
Asterios Karagiannis
1, Dimitri P . Mikhailidis
5; for the Assessing The Treatment Effect in Metabolic
Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group
Abstract
Introduction: Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation
of metabolic syndrome (MetS), is common and accounts for 80% of cases of
elevated liver function tests (LFTs). We assessed the long-term effects of
multifactorial intervention on LFTs and their association with cardiovascular
disease (CVD) events in patients with MetS without diabetes mellitus or CVD.
Material and methods: This prospective, randomized, open label study included
1,123 patients (aged 45-65 years). Patients received intensive lifestyle
intervention and pharmacotherapy: atorvastatin in all patients (low density
lipoprotein cholesterol [LDL-C] targets of < 100 mg/dl [group A] or < 130 mg/dl
[group B]), inhibitors of the renin-angiotensin-aldosterone axis for hypertension,
metformin for dysglycaemia and orlistat for obesity. 
Results: Among participants, 326 had modestly elevated LFTs and ultra  -
sonographic (US) evidence of NAFLD (165 patients in group A2 and 161 patients
in group B2). The NAFLD resolved during the 42-month treatment period in 86%
of patients in group A2 and in 74% of patients in group B2 (p < 0.001). In both
groups nearly 90% of patients attained lipid goals. Mean LDL-C and TG levels
were higher in group B2 than in group A2 (p < 0.001). There were no CVD events
in group A2 whereas 5 non-fatal events occurred in group B2 (log-rank-
p = 0.024). There were no major side-effects.
Conclusions: Attaining multiple treatment targets is safe and beneficial in
primary prevention patients with MetS and NAFLD. Lipid levels and LFTs
normalized, US findings associated with NAFLD resolved and no CVD events
occurred in patients with LDL-C levels < 100 mg/dl (group A2). Resolution of
NAFLD might have contributed to the prevention of CVD events.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is a term
used for a wide spectrum of hepatic pathology
ranging from simple steatosis to non-alcoholic
steatohepatitis (NASH) and cirrhosis in individuals
who do not consume large amounts of alcohol [1].
There is growing interest in NAFLD because it
accounts for approximately 80% of cases of elevated
liver function tests (LFTs) in the American population
and it affects approximately 20-25% of American
adults [2-4]. Reports from Japan and Italy suggest
a similar prevalence [5, 6]. In simple steatosis,
present in up to 30% of the general population and
in 75% of obese patients, triglycerides (TGs)
accumulate in hepatocytes, occupying more than
5% of their volume. Simple steatosis has been
reported to be associated with increased body mass
index (BMI), abnormal glucose tolerance, insulin
resistance and other components of the metabolic
syndrome (MetS) [1, 7]. Accordingly, NAFLD is
considered by some as the hepatic manifestation of
MetS [8]. In turn, MetS confers an increased risk for
cardiovascular disease (CVD) morbidity and mortality
[9, 10] and all-cause mortality [9], even in the
absence of CVD and/or diabetes mellitus (DM) [10,
11]. Patients with NAFLD have 69% higher all-cause
mortality rates than the general population; patients
with NASH have an even higher rate [12]. These
higher rates are mainly due to CVD events and to
a lesser extent due to liver disease-associated
mortality [12]. In patients with both NAFLD and MetS
the CVD risk appears to be even higher [8]. 
We recently showed that statin treatment, on
top of optimal secondary prevention therapy, is safe
and can improve LFTs and reduce CVD morbidity in
patients with coronary heart disease with modestly
abnormal LFTs, possibly due to NAFLD [13]. However,
there are no data on the effect of multifactorial
treatment, including a statin, on NAFLD and the
related CVD events in primary prevention patients
with MetS. This post hoc analysis of the Assessing
The Treatment Effect in Metabolic Syndrome
Without Perceptible diabeTes (ATTEMPT) study [14]
was undertaken to address this issue. 
Material and methods
The study protocol was described in detail in the
original paper [14]. 
  Study population
This is a prospective, randomised, target-based,
intention-to-treat, open label study on a selected
sample from throughout Greece. All participants
had to meet the American Heart Association
diagnostic criteria [15] for MetS and attended the
participating outpatient clinics, considered to
specialise in at least 1 MetS component. Specifically,
at least 3 of the following criteria should be present:
TG levels > 150 mg/dl (1.7 mmol/l); high density
lipoprotein cholesterol (HDL-C) levels < 40 mg/dl
(1.0 mmol/l) for men or < 50 mg/dl (1.3 mmol/l) for
women; blood pressure (BP) > 130/85 mmHg or
treatment for the latter 3 conditions; waist
circumference (WC) > 102 cm in men or > 88 cm 
in women; and fasting plasma glucose (FPG) 
> 100 mg/dl (5.6 mmol/l) [15].
Exclusion criteria in our study were as follows:
TG levels > 500 mg/dl (5.6 mmol/l), pregnancy or
lactation, hormone replacement therapy, active
hepatic disease (known hepatitis or unexplained
persistent transaminases elevation > 100 IU/l),
secondary or resistant hypertension, advanced
chronic kidney disease (CKD) (estimated glomerular
filtration rate < 30 ml/min/1.73 m2) and the
presence of CVD and/or DM (FPG ≥ 126 mg/dl 
(7 mmol/l) and/or glycosylated haemoglobin (HbA1c)
> 6%]. The CVD was excluded on the basis of
personal history, physical examination and if
needed an exercise stress test. Among screened
patients, 1,320 agreed to be followed for a longer
period (3.5 years) and 1,123 had the appropriate age
range (45-65 years old) for CVD risk score
estimation and were enrolled in the study and were
randomised to the 2 treatment groups using block
(of 4) rando  mization. Randomization was perfor  -
med by VGA and the rest of the investigators were
blinded to treatment.
Study protocol
The protocol of the ATTEMPT study included
multifactorial targeting of all CVD risk factors,
including components of the MetS, in all patients
during a 42-month period.
Lifestyle advice: All subjects received lifestyle
advice. This included exercise (walking for at least
30 min 5 days a week (150 min) or equivalent
exercise) and hypolipidaemic (National Cholesterol
Education Program Adult Treatment Panel III)
hypocaloric diet [15]. At baseline there was an
interview with a qualified dietician. Dietary
preferences were recorded and a specific 7-day
diet sheet was handed to the patient at every
visit. Daily calorie intake was set at 500 calories
below the needs of the patient according to
physical activity. 
Treatment of hypertension: Hypertension was
treated in a stepwise manner with 5 mg/day
(titrated up to 40 mg/day) of quinapril. If this was
not enough to reach the treatment target,
amlodipine (titrated from 5 to 10 mg/day), and then
low-dose hydrochlorothiazide (12.5 mg/day) were
added. If one more antihypertensive drug was
required, then central acting antihypertensives, low
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dose selective β-blockers, and finally any other drug
were added to reach the treatment target. The
intention was to avoid any metabolic side-effects
of antihypertensive drug treatment. 
Treatment of obesity: In patients with obesity
(BMI > 30 kg/m2) orlistat (up to 360 mg/day) was
prescribed throughout the study period.
Treatment of impaired fasting glucose (IFG): The
IFG was treated with metformin in patients with
FPG > 110 mg/dl (6.1 mmol/l). The starting dose was
850 mg/day and was increased to 1,700 mg/day if
FPG levels remained > 110 mg/dl (6.1 mmol/l).
Treatment of dyslipidaemia: Atorvastatin was
administered to all subjects; these were randomly
allocated to 2 treatment groups. Group A: LDL-C
target < 100 mg/dl (n = 566) and group B: LDL-C
target of < 130 mg/dl (n = 557). The atorvastatin
dose was titrated from 10 to 80 mg/day.
The study protocol was approved by the local and
national ethics committees and written informed
consent was obtained from each participant before
enrolment. The trial was registered 6 years ago in
the official government of USA ClinicalTrials.gov (Trial
registration number: ID: NCT00416741).
Investigated parameters
Data collected from the study subjects included
a detailed personal medical history, measurements
of the components of the MetS (blood lipids, BP,
FPG and WC), as well as other CVD risk factors
(sex, age, BMI, smoking status and family history
of premature CVD). Blood samples were collected
after a 12 h fast (water allowed) between 8 and
10 am, in a sitting position. Total cholesterol, 
HDL-C and TG levels were determined. The LDL-C
was calculated by the Friedewald formula (LDL-C
[mg/dl] = TC [mg/dl] – (TG [mg/dl]/5 + HDL-C
[mg/dl])). Serum alanine aminotransferase (ALT),
aspartate amino  transferase (AST), γ-glutamyl
transpeptidase (γ-GT), alkaline phosphatase (AP),
creatinine (SCr), uric acid (SUA) and creatine
kinase (CK) were also assessed. Estimated
glomerular filtration rate (eGFR ml/min/1.73 m2)
was measured using the Modification of Diet in
Renal Disease equation: eGFR = 175 × (SCr)–1.154
× (age)–0.203 × (0.742 if female) [http://www.
nkdep.nih.gov/professionals/ gfr_calculators/idms_
con.htm]. Biochemical evaluation was carried out
in various laboratories that fulfilled internal and
external validity control criteria. All measurements
in the same centre were performed by the same
lab, using the same methods, and therefore results
are comparable. In patients with raised LFTs,
abdominal ultrasound (US) was performed, and
when US findings were suggestive of NAFLD, the
patient was characterized as having NAFLD.
Endpoints
The primary endpoint of the original study was
the reduction in the 10-year eCVD risk at 
6 months compared with baseline (of the
interventional part of the study, and not the
baseline of the epidemiological part of the study)
in the total study population (n = 1,123). The
secondary endpoints were the eCVD risk
reduction during the next 3 years, the proportion
of patients having MetS at the 42nd month of
treatment and the number of CVD events
(unstable angina (UA), myocardial infarction (MI),
percutaneous coronary intervention (PCI),
coronary artery bypass grafting (CABG), stroke,
transient ischaemic attack (TIA) and CVD death)
in all participants. In the present post hoc analysis
the primary endpoint was the effect of
multifactorial treatment on the prevalence of
NAFLD in patients with MetS and NAFLD in both
treatment groups (n = 326) and its relation with
actual CVD events during the 42-month follow-
up. The secondary endpoint was the relation of
NAFLD with chronic kidney disease (CKD).
Safety
A clinical and laboratory (ALT, AST, CK, SCr) investi  -
gation was performed every 6 months at program  -
med study visits (there were 10-12 such visits).
Statistical analysis
Intention-to-treat analysis of all patients
randomized to the 2 treatment groups was per  -
formed. Continuous variables are presented as mean
± standard deviation (SD) since all parame  ters were
normally distributed according to the Kolmogorov-
Smirnov test. Qualitative variables are presented as
relative frequencies. Clinical and laboratory findings
between groups were compared by ANOVA. Unpaired
Student's t-tests were used for comparisons of
parametric data and χ2 tests for comparisons of
categorical data between the 2 groups at specific time
points. The log-rank test was used to compare CVD
event rates in the 2 treatment groups. A two-sided
p < 0.05 was considered significant. All analyses were
carried out using the SPSS 19.00 software package
(SPSS, Inc., Chicago, IL).
Results
At baseline, 326 patients had modestly elevated
LFTs and US evidence of NAFLD (165 patients in
group A2 and 161 patients in group B2).
Effect of treatment on LFTs in patients with US
evidence of NAFLD
There was a substantial reduction in all liver
enzyme activities in patients with raised LFTs at
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baseline and US evidence of NAFLD. In group A2 ALT
was reduced by 48% (from 60 ±11 IU/l to 31 ±5 IU/l;
p < 0.001), AST by 47% (from 51 ±10 IU/l to 27 ±4
IU/l; p < 0.001), γ-GT by 60% (from 91 ±15 IU/l to 
36 ±6 IU/l; p < 0.001) and AP by 43% (from 171 ±28
IU/l to 85 ±9 IU/l; p < 0.001) during the 42-month
follow-up (Table I and Figure 1, panel 1). In group B2
ALT was reduced by 42% (from 61 ±12 IU/l to 35 ±6
IU/l; p < 0.001), AST by 40% (from 52 ±11 IU/l to 
31 ±6 IU/l; p < 0.001), γ-GT by 52% (from 93 ±14 IU/l
to 44 ±6 IU/l; p < 0.001) and AP by 40% (from 169
±32 IU/l to 101 ±15 IU/l; p < 0.001) during the 
42-month follow-up (Table I and Figure 1, panel 2).
Reductions in ALT, AST, γ-GT and AP in group A2
were larger than in group B2 (p < 0.05 for all 
4 comparisons).
At the end of the study, 86% (n = 142) of the
patients in group A2 had normal LFTs and no US
evidence of NAFLD, 8% (n = 13) had normal LFTs
but US evidence of NAFLD and 6% (n = 10) had both
elevated LFTs and US evidence of NAFLD. In group
B2, at the end of the study 74% of the patients 
(n = 119) had normal LFTs and no US evidence of
NAFLD, 15% (n = 24) had normal LFTs but some US
evidence of NAFLD and 11% (n = 18) had both
elevated LFTs and US evidence of NAFLD. NAFLD
resolution rate was higher in group A2 than in
group B2 (86 vs. 74%; p = 0.0012).
Parameter Patients with abnormal LFTs at baseline (n = 326)
Group A2 (n = 165) Group B2 (n = 161)
Baseline 42 months Value of p Baseline 42 months Value of p
Age [years] 58 ±7 – – 57 ±9 – –
Family history of CVD [%] 34 – – 36 – –
Smoking [%] 33 25 < 0.001 32 25 < 0.001
Body mass index [kg/m2] 33 ±4 29 ±4 < 0.001 32 ±5 29 ±3 < 0.001
Weight [kg] 89 ±14 82 ±11 < 0.001 89 ±13 83 ±12 < 0.001
Systolic blood pressure [mmHg] 145 ±13 125 ±9 < 0.001 144 ±11 124 ±10 < 0.001
Diastolic blood pressure [mmHg] 91 ±9 80 ±4 < 0.001 90 ±10 79 ±5 < 0.001
HDL-C [mg/dl] 45 ±11 52 ±7 < 0.001 46 ±10 51 ±8 < 0.001
Triglycerides [mg/dl] 220 ±47 123 ±20 < 0.001 218 ±50 142 ±34* < 0.001
Waist circumference [cm] 105 ±9 98 ±8 < 0.001 104 ±11 99 ±7 < 0.001
Blood glucose [mg/dl] 106 ±12 98 ±9 < 0.001 107 ±13 97 ±8 < 0.001
Total cholesterol [mg/dl] 255 ±44 165 ±24 < 0.001 256 ±41 186 ±26* < 0.001
LDL-C [mg/dl] 168 ±38 92 ±12* < 0.001 171 ±36 110 ±20* < 0.001
Metabolic syndrome [%] 100 15 < 0.001 100 16 < 0.001
Abdominal obesity [%] 90 50 < 0.001 91 52 < 0.001
Hypertension [%] 85 11 < 0.001 84 10 < 0.001
High TG levels [%] 79 10 < 0.001 80 12 < 0.001
Impaired fasting glucose [%] 72 9 < 0.001 71 8 < 0.001
Low HDL-C [%] 61 8 < 0.001 60 7 < 0.001
ALT [IU/l]) 60 ±11 31 ±5 < 0.001 61 ±12 35 ±6* < 0.001
AST [IU/l] 51 ±10 27 ±4 < 0.001 52 ±11 31 ±6* < 0.001
γ-GT [IU/l] 91 ±10 36 ±5 < 0.001 93 ±11 44 ±6* < 0.001
Alkaline phosphatase [IU/l] 171 ±28 86 ±9 < 0.001 169 ±32 101 ±15* < 0.001
CVD events  Expected events: 8-11  Expected events: 10-13 
actual CVD events: 0 actual CVD events: 5 (p = 0.024)
*p < 0.001 vs. group A2, MetS – metabolic syndrome, NAFLD – non-alcoholic fatty liver disease, LFTs – liver function tests, CVD – cardiovascular
disease, LDL-C – low density lipoprotein cholesterol, HDL-C – high density lipoprotein cholesterol, TG – triglycerides, ALT – alanine aminotransferase,
AST – aspartate aminotransferase
Table I. Characteristics of patients with MetS and NAFLD according to treatment allocation (group A2, LDL-C target
< 100 mg/dl; group B2, LDL-C target < 130 mg/dl)
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Effects of treatment on other parameters in
patients with NAFLD
Multifactorial treatment in patients with NAFLD
Atorvastatin was used in all patients with forced
dose titration (10 mg/day to 80 mg/day). In patients
with NAFLD, the mean dose of atorvastatin during
the study was 34 mg/day and 24 mg/day in 
group A2 and B2, respectively. The adherence to
atorvastatin during the study was high (92%). The
LDL-C and TGs were significantly higher (p < 0.05) in
group B2 than in group A2 during the study (Table I).
Hypertension was treated with quinapril (mean dose
20 mg/day in both groups; n = 229, 70% of patients)
and if needed with amlodipine (mean dose 
8 mg/day in both groups; n = 131, 40% of patients),
and then, if needed, with hydrochlorothiazide (mean
dose 12.5 mg/day in both groups; n = 83, 25% of
patients). About 28% of patients were on
angiotensin receptor blockers (ARBs), 12% on
centrally acting antihypertensive drugs, 10% on 
β-blockers and 17% on various other antihy  -
pertensive agents. In patients with evidence of
NAFLD and a BMI > 30 kg/m2, orlistat was used in
a mean dose of 290 mg/day (n = 169). Metformin
was used in a mean dose of 950 mg/day in 152
patients with IFG.
The use of drugs comprising the multifactorial
intervention and the doses administered (with the
exception of atorvastatin) did not differ between
treatment groups (Table I). Only the atorvastatin
doses used and the lipid values achieved differed
significantly between the 2 treatment groups.
Changes in measured parameters in patients
with NAFLD
MetS components: The most common MetS
component was central obesity, followed by
hypertension and high TG and FPG levels and lastly
HDL-C. The most prevalent phenotype (19%) was
that with elevated BP (or on antihypertensive
treatment), increased WC, high TGs and increased
FPG. Baseline LDL-C levels were 170 mg/dl. None of
the measured parameters differed significantly
between groups A2 and B2 at baseline. At the end
of the study, only 10% of the patients with NAFLD
still had MetS (persistent cases), but with fewer
components.
Lipid levels: At the 42nd treatment month LDL-C
was substantially reduced in both groups (92 ±12
mg/dl in group A2 vs. 110 ±20 mg/dl in group B2, 
p < 0.001) (Table I). Approximately 90% of the study
population achieved the allocated LDL-C target 
(< 100 mg/dl in group A2 and < 130 mg/dl in 
group B2; Table I). Patients in group A2 had lower
TG levels than group B2 (123 ±20 mg/dl vs. 142 
±34 mg/dl, p < 0.001). The HDL-C levels showed
a comparable increase in both groups.
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Figure  1.  Time course of changes in alanine
aminotransferase (ALT), aspartate aminotransferase
(AST), γ-glutamyl transpeptidase (γ-GT), and alkaline
phosphatase (AP) levels (panel 1 for group A2 
(n = 165) and panel 2 for group B2 (n = 161)) and
event-free survival during the study in groups A2 and
B2 (panel 3) 
*p < 0.05 vs. baseline, group A2 – patients with an LDL-C
target < 100 mg/dl, group B2 – patients with an LDL-C target
< 130 mg/dl
Event free survival of A2 and B2
LTs in group B2
LTs in group A2
log-rank p = 0.024
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Renal function: A substantial proportion of
patients with NAFLD (137/326, 42%) had stage 
3 CKD (eGFR 30-59 ml/min/1.72 m2). This proportion
was higher than in patients without NAFLD
(212/797, 26%; p < 0.001). In patients with NAFLD
and stage 3 CKD, eGFR was increased by 13% vs.
baseline (p < 0.001).
Other CVD risk factors: The BMI, FPG levels and
the prevalence of hypertension were significantly re  -
duced during the 42 months of treatment (Table I).
Smaller but significant improvements were
observed in WC.
New onset diabetes (NOD): The incidence of NOD
during the 42-month follow-up was very low, 0.83-
1.00/100 patient-years in patients with MetS and
MetS with impaired fasting glucose, respectively.
High sensitivity C-reactive protein (hsCRP) levels:
The hsCRP levels declined in group A2 more than
in group B2 (from 4.0 mg/l at baseline to 0.7 mg/l
at 42 months in group A2 (p < 0.001) and from 
4.1 mg/l to 1.4 mg/l over the same time period in
group B2 (p < 0.001); p < 0.05 for the comparison
between the 2 groups during the entire study).
The CVD events in NAFLD patients 
During the first 6 months there were no CVD
events among the 326 participants with NAFLD.
Between the 6th and the 42nd month there was no
CVD event in group A2 (Table I and Figure 1, 
panel 3) whereas 5 non-fatal CVD events (3 non-
fatal MIs and 2 PCIs) occurred in group B2 
(p = 0.0024, Table I).
Effect of treatment on LFTs in patients without
US evidence of NAFLD
At baseline 42 patients, apart from the 326 with
NAFLD, had elevated LFTs without US confirmation
of NAFLD. These had ALT and AST values similar to
those of the 326 NAFLD patients but lower values
of γ-GT and AP (65 ±14 IU/l and 132 ±13 IU/l vs. 
92 ±12 and 170 ±25 IU/l, respectively; p < 0.05). The
reduction in both ALT and AST during the study was
lower than that achieved in the 326 NAFLD patients
(26 vs. 45% in ALT and 24 vs. 43% in AST values 
(p < 0.05 in comparison to the reduction of ALT and
AST values in the 326 NAFLD patients)).
Discussion 
We recently reported that statin treatment is
safe and can improve LFTs and reduce CVD
morbidity and mortality in secondary prevention
patients with modestly abnormal LFTs that were
attributable to NAFLD [13]. To our knowledge, the
present study is the first prospective, randomized,
intention-to-treat, controlled trial to assess the
effects of multifactorial intervention on LFTs and
related CVD events in primary prevention patients
with NAFLD. The key findings are that this
multifactorial intervention results in an improve  -
ment of LFTs and reduces the CVD event rate. These
findings could be attributed to intensive ator  -
vastatin treatment and lower lipid levels, because
reductions in LFTs and CVD events in group A2 (with
an LDL-C < 100 mg target) were superior to those
in the less aggressive group B2 (with an LDL-C
target < 130 mg/dl), while all other risk factors and
interventions were similar in these 2 groups.
Visceral obesity, impaired glucose metabolism,
hypertension and dyslipidaemia are prevalent in
NAFLD, and this might play a role in the increased
CVD risk in NAFLD patients [16]. However, it appears
that NAFLD per se might be independently related
to increased CVD risk [17-19]. In NAFLD, insulin
resistance is related to elevated levels of markers
of inflammation, such as CRP and fibrinogen [17].
Moreover, in obesity/NAFLD visceral adipocytes are
a major source of the increase in circulating
proinflammatory, prothrombotic and proathe  -
rogenic factors, collectively termed adipokines,
which include tumour necrosis factor-α, leptin,
plasminogen activator inhibitor-1, interleukin-6 and
angiotensinogen, whereas levels of adiponectin,
which has antidiabetic, anti-atherogenic and anti-
inflammatory properties, are substantially reduced
[17, 18]. Thus, increased pro-atherogenic factors and
decreased plasma levels of adiponectin may
represent another possible mechanism linking
NAFLD and CVD [17-19]. Most of these factors
appear to normalize during statin treatment [20]. 
Given the multifactorial pathogenesis of NAFLD,
numerous treatments for various contributory risk
factors have been proposed in the past, but there
is no single established intervention to be
recommended for all cases irrespective of the
primary NAFLD risk factor [21]. Weight loss and
increased physical activity constitute the
cornerstone of NAFLD treatment [21]; however, the
compliance of patients to long-term lifestyle
modifications is low and therefore pharmacotherapy
is frequently necessary [22, 23]. Even modest weight
loss (7-10% of body weight) in overweight patients
with NAFLD has been shown to improve LFTs [24].
In addition, improvement or resolution of obesity
and MetS has been associated with major
improvements in lobular steatosis as well as in liver
necroinflammation and fibrosis [24, 25]. In ATTEMPT,
intensive lifestyle measures resulted in a 7.3%
weight loss in NAFLD patients (Table I). The use of
orlistat is a safe adjunct to intensive lifestyle
measures for weight loss [26]. Orlistat, either
monotherapy or in combination therapy, also
appears to be beneficial in NAFLD [26-30]. In the
present study, significant reductions were observed
in body weight, BMI and WC, and there is evidence
that weight loss induced by orlistat might reverse
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fatty infiltration of the liver and improve insulin
resistance and even hepatic fibrosis in obese
patients with NAFLD [31]. Thus, the use of orlistat
in 51% of our patients might have contributed to
the resolution of NAFLD.
It has also been shown that both metformin and
dietary treatment alone ameliorate liver steatosis
and metabolic abnormalities in patients with NAFLD
[32]. However, metformin plus diet was more
effective than dietary treatment alone in
normalizing several metabolic parameters in these
patients [32]. In contrast to thiazolidinediones,
metformin has been shown to improve biochemical
markers in NAFLD patients without inducing weight
gain [33-35]. In addition, an improvement in body
composition and fat distribution as well as
a reduction in liver necroinflammation was
observed in patients treated with metformin [22].
Thus, the use of metformin by 46% of our patients
might have also played a role in the resolution of
NAFLD.
Hypertension appears to be associated with
NAFLD [36], and in the ATTEMPT study, hyper  -
tension was the most prevalent MetS component
[14]. The renin-angiotensin-aldosterone system
(RAAS) plays a role in increasing insulin resistance
whereas RAAS suppression improves intracellular
insulin signalling through activation of PPAR-γ
receptors [37-39]. This effect attenuates hepatic
inflammation and fibrogenesis, which translate into
clinical and histological improvement in NAFLD 
[37-39]. Thus, the fact that 70% of our patients were
on an ACE-I and 28% on an ARB might have
contributed to the improvement in LFTs [36].
Nevertheless, all the above treatments, except
for atorvastatin, were equally administered to both
treatment groups. Therefore, we mainly attribute
the greater reductions in LFT values, higher rates
of NAFLD resolution and lower CVD incidence in
group A2 compared with group B2 to more
aggressive treatment with atorvastatin. The
pleiotropic effects of statins, which also appear to
be dose related, might have also played a role in
the improved outcome of patients who received
higher atorvastatin doses [16, 40].
We have previously shown that atorvastatin
alone or in combination with fenofibrate normalizes
LFTs and US findings in patients with NAFLD, free
of DM and CVD at baseline [41]. These effects were
independently related to statin treatment as well
as to reductions in WC, body weight, systolic BP and
serum hsCRP, TG, LDL-C, total cholesterol and FPG
levels [41]. Other studies have also shown that
statins are safe and effective in patients with
elevated LFTs because of NAFLD [42, 43]. In a study
with histopathological follow-up, NAFLD patients
who were on statins exhibited significant reductions
in liver steatosis as opposed to patients who were
not taking statins [43]. Recently, we showed in
patients with coronary heart disease that, besides
the resolution of LFTs and improvement in US
findings, statin treatment reduced CVD events more
in patients with NAFLD than in those without
NAFLD (68% vs. 39%, respectively; p = 0.007) 
[13, 44]. The present post hoc analysis of the
ATTEMPT study suggests, for the first time in
primary prevention, that a higher atorvastatin dose
(34 mg/day), which achieved lower LDL-C and TG
levels, reduced LFTs values and CVD events more
than a lower dose of atorvastatin (24 mg/day). This
suggests that to achieve maximum benefit, more
aggressive LDL-C targets should be pursued for
dyslipidaemia associated with MetS-related NAFLD.
In ATTEMPT, the differences in LDL-C and TG levels
between groups A2 and B2 were 18 and 19 mg/dl,
respectively (Table I), whereas there was no
significant difference in HDL-C levels between the
2 treatment groups. There are no survival studies
that included patients with MetS and NAFLD.
However, our findings concur with the effects of
atorvastatin on lipids and on CVD incidence in
a post hoc analysis of the Treating to New Targets
(TNT) trial in patients with MetS [45]. In patients
with CVD and MetS included in TNT, the mean 
on-treatment LDL-C concentrations at 3 months
were 99 mg/dl with atorvastatin 10 mg/day and 
72 mg/dl with atorvastatin 80 mg/day (a difference
of 27 mg/dl; p < 0.001), TGs were 148 mg/dl and
176 mg/dl respectively (a difference of 28 mg/dl; 
p < 0.001) and there was no significant difference
in HDL-C levels between the 2 treatment groups
[45]. At a median follow-up of 4.9 years, major CVD
events occurred in 13% of the patients receiving
atorvastatin 10 mg/day and in 9.5% of the patients
receiving atorvastatin 80 mg/day (29% reduction,
p < 0.001) [45]. Similar findings were observed in
MetS patients without DM [45]. A subsequent
subgroup analysis of the Scandinavian Simvastatin
Survival Study showed that patients with MetS
benefited from simvastatin therapy by at least as
much as those without MetS, despite the relatively
high baseline (190 mg/dl) and on-study (120 mg/dl)
values of LDL-C [46]. 
Another possible explanation for NAFLD
resolution and additional CVD clinical benefit
induced by atorvastatin is that liver TG increase is
linked with decreased expression of PPAR-α, which
is prevented by atorvastatin treatment [47]. The
increase in PPAR-α expression caused by ator  -
vastatin is associated with reduced liver TGs and
plasma non-esterified fatty acid levels, because of
increased hepatic fatty acid β-oxidation activity [47].
Moreover, atorvastatin can ameliorate the very low
density lipoprotein (VLDL) apolipoprotein B
overproduction state observed in a fructose-fed,
insulin-resistant hamster model, and may also
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improve hepatic insulin sensitivity [48]. In addition,
MetS-induced abnormalities in plasma markers of
inflammation and haemostasis and in monocyte
secretory functions are ameliorated by atorvastatin
[49]. Indeed, in ATTEMPT a substantial fall in 
hsCRP levels was recorded. Finally, atorvastatin
substantially reduced SUA levels, which are also
implicated in NAFLD-related CVD risk [50]. 
We also observed a significant association
between NAFLD and the risk of CKD, 2 inde  -
pendent CVD risk factors [51], which share many
important cardio-metabolic risk factors [52]. The
prevalence of stage 3 CKD among NAFLD patients
was higher than in those without NAFLD (42% vs.
26%; p < 0.001), suggesting a common patho  -
physiology [52, 53]. Inter-related risk factors,
dyslipidaemia and proinflammatory/procoagulant
mediators from the fatty/inflamed liver, might play
a role in the natural history of obesity-related
kidney and liver disease [52, 53]. The coexistence
of these 2 risk factors appears to further increase
the CVD risk [19, 51]. We showed in another post
hoc  analysis of ATTEMPT that multifactorial
treatment improves renal function and lowers SUA
levels in patients with stage 3 CKD [54]. This is
also true for patients with NAFLD and CKD (a 13%
increase in eGFR was observed) and might have
acted in conjunction with NAFLD resolution to
minimize CVD events in patients with MetS,
NAFLD and CKD. The fact that the incidence of
NOD during the 42-month follow-up was very low
(0.83-1.00/100 patient-years) in patients with MetS
and MetS with impaired fasting glucose,
respectively, might have contributed to the low
incidence of CVD in our patients [55].
Our findings suggest that atorvastatin therapy
might prevent hepatocellular damage [56]. It was
shown that the combination of atorvastatin with
a standard diet yields greater improvements in
NASH [56]. Thus, atorvastatin therapy not only
decreases the levels of cholesterol and TGs, but
might also induce a reduction of liver steatosis,
inflammation and hepatocellular damage, which
will translate to reduction of LFT values [56].
It is possible that most of the 42 patients who
had elevated LFTs without US findings of NAFLD
had indeed a "milder" form of NAFLD (with less fat
deposition). These patients had significant but
smaller reductions in ALT and AST than those with
both LFT elevations and US findings of NAFLD 
(n = 326). One possible explanation is that
multifactorial treatment significantly reduced the
higher liver fat content in the latter patients, leading
to a greater reduction of LFTs.
This study has several limitations. This is a post
hoc analysis of the original survival study with MetS
patients having NAFLD. We did not perform biopsies
to diagnose NAFLD or its resolution after treatment.
Biopsy is the “gold standard” for diagnosis of
NAFLD; hence we tried to strengthen our diagnostic
criteria in the light of ethical restrictions associated
with liver biopsies (especially if this would be
required before and after treatment in a large
number of patients). This is why we included both
features, LFTs and US. The number of patients
analysed is relatively small. Generalisability of study
findings will be reinforced by prospective data of
larger studies.
In conclusion, within a multifactorial treatment,
it is safe to prescribe statins in primary CVD
prevention patients with MetS and NAFLD with
modestly elevated LFTs. The LFTs are gradually
reduced and US findings improve during long-term
statin treatment. Moreover, there is a substantial
reduction in CVD events when lipid targets are
attained. These findings support our earlier
suggestion for statin use in NAFLD treatment [57].
Given the high prevalence of NAFLD and its role as
a CVD risk factor, properly designed, prospective
studies are needed to confirm these findings and
allow the incorporation of statin treatment as
a major component of NAFLD therapy.
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